For clinical purposes, i.e., to mediate ADCC, it is interesting to produce NK cells with high CD16a expression, such as the protocol that we have recently described (71), which produces cells with efficient ADCC against primary tumor cells (72, 73). This evidence concerns the gene FCGR3A and neoplasm.